Endocrine Disruption Screening Market is expected to reach US$ 153.30 Million by 2028

Published Date: 29 Nov 2021

Report : Endocrine Disruption Screening Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Assay Type (In-Vitro and In-Vivo), Application (Natural Materials and Synthetic Materials), Sources of Waste (Incineration and Landfill, Agricultural Runoff, Industrial and Municipal Effluents, Pulp Mill Effluents, Consumer Products, and Others), Method [Estrogen Receptor (ER) Transactivation, Androgen Receptor (AR) Transactivation, Androgen Receptor (AR) Modulation, Estrogen Receptor-Alpha (ER-Alpha) Binding, Estrogen Receptor-Beta (ER-Beta) Binding, Androgen Receptor (AR) Binding, Steroidogenesis, Aromatase Assay, and Others], and End User (Pharmaceutical and Biopharmaceutical Companies, Cosmetics and Household Product Companies, Food Industry, and Chemical Industry) and Geography

By Assay Type the In-Vitro Segment is expected to Lead Market during 2021–2028


According to our new research study on “Endocrine Disruption Screening Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Assay Type, Application, Source of Waste, Method, End-User and Geography,” the market is expected to reach US$ 153.30 million by 2028 from US$ 126.53 million in 2021; it is estimated to grow at a CAGR of 2.8% during 2021–2028. The report highlights trends prevailing in the market and factors driving its growth. The growth of the market is attributed to the growing research in the biotechnology sector and the rising prevalence of endocrine disorders. However, the high cost of screening technology hampers the market growth.


Based on assay type, the endocrine disruption screening market is bifurcated into in-vitro and in-vivo. The in-vitro segment held a larger share of the market in 2021 and is anticipated to register a higher CAGR in the market during the forecast period. The in vitro Estrogen Receptor (ER) binding experiment assesses the capacity of the radiolabeled ligand [3H]17β-estradiol ([3H]-E2) to interact with the ER in the presence of increasing quantities of a test item (i.e., competitor). Test items that possess a high affinity for the ER compete with the radiolabeled ligand at a lower concentration as compared with those compounds with lower affinity for the ER.  


Impact of COVID-19 Pandemic on Endocrine Disruption Screening Market

The COVID-19 pandemic is adversely affecting industries worldwide. The outbreak led to significant disruptions in primary industries, such as manufacturing, healthcare, energy & power, electronics & semiconductor, aerospace & defense, and construction in 2020. The pandemic had a negative impact on the total sales of most companies, whereas it had a favorable impact on the endocrine disruption screening market due to the increased usage of endocrine disruption screening technologies for various hormonal disorders. The lockdown due to the COVID-19 pandemic has forced people to put off getting their hormonal health checked, thus affecting the number of tests being performed and sales of screening products. Due to the COVID-19 pandemic, dealing with hormonal and mental health has become a major medical concern across the world.


Creative Bioarray; Charles River Laboratories, Inc; Eurofins Scientific; Alpha Analytical, Inc.; JRF Global; Xenometrix AG; SGS SA; Smithers; and Mérieux NutriSciences are among the leading companies operating in the endocrine disruption screening market.

Endocrine Disruption Screening Market, by Region, 2021 (%)

Endocrine Disruption Screening Market, by Region, 2021 (%)

The endocrine disruption screening market, by assay type, is bifurcated into in-vitro and in-vivo.  Based on application, the market is bifurcated into natural materials and synthetic materials. Based on source of waste, the endocrine disruption screening market is segmented into incineration and landfill, agricultural runoff, industrial and municipal effluents, pulp mill effluents, consumer products, and others. Based on method, the market is segmented into estrogen receptor (ER) transactivation, androgen receptor (AR) transactivation, androgen receptor (AR) modulation, estrogen receptor-alpha (ER) binding, estrogen receptor beta (ER) binding, androgen receptor (AR) binding, steroidogenesis, aromatase assay, and others. Based on end user, the endocrine disruption screening market is segmented into pharmaceutical and biopharmaceutical companies, cosmetics and household product companies, food industry, and chemical industry.  By geography, the endocrine disruption screening market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East and Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Contact Us
Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com
Download Free PDF Brochure